Sai Parenterals Ltd
Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing.[1]
- Market Cap ₹ 2,590 Cr.
- Current Price ₹ 586
- High / Low ₹ 706 / 400
- Stock P/E 154
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 7.03 %
- ROE 5.80 %
- Face Value ₹ 5.00
Pros
Cons
- Company has a low return on equity of 8.00% over last 3 years.
- Company has high debtors of 183 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 97 | 114 | 124 | 162 | |
| 79 | 92 | 97 | 132 | |
| Operating Profit | 18 | 21 | 27 | 31 |
| OPM % | 18% | 19% | 22% | 19% |
| 0 | 1 | 0 | 3 | |
| Interest | 5 | 6 | 7 | 9 |
| Depreciation | 6 | 6 | 5 | 6 |
| Profit before tax | 7 | 10 | 14 | 19 |
| Tax % | 37% | 30% | 28% | 11% |
| 5 | 7 | 10 | 17 | |
| EPS in Rs | 6.43 | 5.40 | 3.88 | 3.80 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 19% |
| TTM: | 31% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 55% |
| TTM: | 62% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 8% |
| Last Year: | 6% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 7 | 13 | 13 | 22 |
| Reserves | 24 | 65 | 78 | 465 |
| 69 | 71 | 72 | 133 | |
| 34 | 45 | 52 | 184 | |
| Total Liabilities | 134 | 194 | 215 | 804 |
| 44 | 41 | 40 | 43 | |
| CWIP | 2 | 0 | 0 | 1 |
| Investments | 0 | 28 | 28 | 158 |
| 88 | 124 | 146 | 602 | |
| Total Assets | 134 | 194 | 215 | 804 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| -21 | -4 | 10 | 112 | |
| -17 | -32 | -4 | -136 | |
| 30 | 36 | -6 | 433 | |
| Net Cash Flow | -8 | -1 | -0 | 409 |
| Free Cash Flow | -38 | -7 | 6 | 105 |
| CFO/OP | -103% | -6% | 51% | 385% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 231 | 272 | 254 | 183 |
| Inventory Days | 83 | 97 | 130 | 208 |
| Days Payable | 140 | 156 | 160 | 89 |
| Cash Conversion Cycle | 174 | 213 | 224 | 302 |
| Working Capital Days | 27 | 70 | 59 | -216 |
| ROCE % | 13% | 14% | 7% |
Insights
In beta| Mar 2026 | |
|---|---|
| CDMO revenue YoY growth % |
|
| Cumulative product registrations in regulated markets count |
|
| Dossiers approved/filed in the year count |
|
| Dossiers developed in-house by R&D subsidiary (cumulative) count |
|
| Dossiers under development (pipeline) count |
|
| Installed manufacturing capacity - Revat Laboratories (Ongole) million units |
|
| Installed manufacturing capacity - Unit I (Injectables) million units |
|
| Installed manufacturing capacity - Unit III (General Oral Dosage Forms) million units |
|
| Installed manufacturing capacity - Unit IV (Cephalosporin Oral Dosage Forms and Injectables) million units |
|
| Number of complex products in portfolio count |
|
| Pharmacy reach in Australia via long-term supply networks count |
|
| Share of consolidated revenue from long-term supply contracts in regulated markets % |
|
| TGA-Australia product registrations count |
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Management
6 Jul - Board appointed secretarial, internal and cost auditors on 06 Jul 2026 and authorized CMD to explore growth opportunities.
-
Board Meeting Outcome for Outcome Of The Board Meeting
6 Jul - Board approved auditors on 6 July 2026 and authorized CMD to explore growth opportunities.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
1 Jul - Noumed renewed exclusive OTC supply deal in Australia for AUD 202 million over 7.5 years, effective July 1, 2026.
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 1 Jul
-
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
1 Jul - Subsidiary Noumed signed exclusive OTC supply agreement worth AUD 202 million for 7.5 years, effective 1 July 2026.
Annual reports
No data available.
Concalls
-
May 2026Transcript PPT
Business Profile[1][2]
Sai Parenteral is a diversified pharmaceutical formulations company engaged in R&D, manufacturing, and commercialization of products across both domestic and international markets. Over time, the company has evolved from being a parenteral-focused player into a full-fledged diversified formulations platform, significantly reducing its dependency on injectables in the process.